by divibasicbldev | Apr 14, 2022 | Press Releases
MIAMI BEACH, Fla., April 14, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for...
by divibasicbldev | Mar 30, 2022 | Press Releases
— Cash Balance of $52.9 million to fund operations well into 2024 —- Initiation of a drug development program in schizophrenia —- Initiation of a drug development program in multiple sclerosis —- Launched ketamine clinics in the U.K. and U.S....
by divibasicbldev | Mar 8, 2022 | Press Releases
– The Glimpse Group is a Virtual Reality and Augmented Reality platform company – Partnership will allow Pasithea to co-develop VR environments for patients with psychiatric disorders MIAMI BEACH, Fla., March 08, 2022 (GLOBE NEWSWIRE) — Pasithea...
by divibasicbldev | Feb 24, 2022 | Press Releases
— Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue — — New London locations will provide pharmacy services, ketamine therapy, and other psychiatric treatments, including repeated transcranial...
by divibasicbldev | Feb 9, 2022 | Press Releases
Newest member is a renowned thought leader in the identification of neurobiological mechanisms of mental illnessMIAMI BEACH, Fla., Feb. 09, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”),...
by divibasicbldev | Feb 3, 2022 | Press Releases
Company commences program to develop a tolerizing vaccine and names Hooke Laboratories as its research partnerMIAMI BEACH, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a...
